BACKGROUND: The macula (central retina) contains a yellow pigment, comprising the dietary carotenoids lutein (L), zeaxanthin (Z), and meso-zeaxanthin, known as macular pigment (MP). The concentrations of MP's constituent carotenoids in retina and brain tissue correlate, and there is a biologically-plausible rationale, supported by emerging evidence, that MP's constituent carotenoids are also important for cognitive function. OBJECTIVE: To investigate if patients with Alzheimer's disease (AD) are comparable to controls in terms of MP and visual function. METHODS: 36 patients with moderate AD and 33 controls with the same age range participated. MP was measured using dual-wavelength autofluorescence (Heidelberg Spectralis®); cognitive function was assessed using a battery of cognition tests (including Cambridge Neuropsychological Test Automated Battery). Visual function was recorded by measuring best corrected visual acuity (BCVA) and contrast sensitivity (CS). Serum L and Z concentrations (by HPLC) and age-related macular degeneration (AMD, by retinal examination) status were also assessed. RESULTS: In the AD group, central MP (i.e., at 0.23°) and MP volume were significantly lower than the control group (p < 0.001 for both), as were measures of BCVA, CS, and serum L and Z concentrations (p < 0.05, for all). CONCLUSION: AD patients were observed to exhibit significantly less MP, lower serum concentrations of L and Z, poorer vision, and a higher occurrence of AMD when compared to control subjects. A clinical trial in AD patients designed to investigate the impact of macular carotenoid supplementation with respect to MP, visual function, and cognitive function is merited.
BACKGROUND: The macula (central retina) contains a yellow pigment, comprising the dietary carotenoids lutein (L), zeaxanthin (Z), and meso-zeaxanthin, known as macular pigment (MP). The concentrations of MP's constituent carotenoids in retina and brain tissue correlate, and there is a biologically-plausible rationale, supported by emerging evidence, that MP's constituent carotenoids are also important for cognitive function. OBJECTIVE: To investigate if patients with Alzheimer's disease (AD) are comparable to controls in terms of MP and visual function. METHODS: 36 patients with moderate AD and 33 controls with the same age range participated. MP was measured using dual-wavelength autofluorescence (Heidelberg Spectralis®); cognitive function was assessed using a battery of cognition tests (including Cambridge Neuropsychological Test Automated Battery). Visual function was recorded by measuring best corrected visual acuity (BCVA) and contrast sensitivity (CS). Serum L and Z concentrations (by HPLC) and age-related macular degeneration (AMD, by retinal examination) status were also assessed. RESULTS: In the AD group, central MP (i.e., at 0.23°) and MP volume were significantly lower than the control group (p < 0.001 for both), as were measures of BCVA, CS, and serum L and Z concentrations (p < 0.05, for all). CONCLUSION:ADpatients were observed to exhibit significantly less MP, lower serum concentrations of L and Z, poorer vision, and a higher occurrence of AMD when compared to control subjects. A clinical trial in ADpatients designed to investigate the impact of macular carotenoid supplementation with respect to MP, visual function, and cognitive function is merited.
Authors: V Polo; M J Rodrigo; E Garcia-Martin; S Otin; J M Larrosa; M I Fuertes; M P Bambo; L E Pablo; M Satue Journal: Eye (Lond) Date: 2017-03-10 Impact factor: 3.775
Authors: R Moran; J M Nolan; J Stack; A M O'Halloran; J Feeney; K O Akuffo; R A Kenny; S Beatty Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: K O Akuffo; J M Nolan; A N Howard; R Moran; J Stack; R Klein; B E Klein; S M Meuer; S Sabour-Pickett; D I Thurnham; S Beatty Journal: Eye (Lond) Date: 2015-05-15 Impact factor: 3.775
Authors: Marina Green-Gomez; Paul S Bernstein; Christine A Curcio; Rachel Moran; Warren Roche; John M Nolan Journal: Transl Vis Sci Technol Date: 2019-12-18 Impact factor: 3.283
Authors: Jirayu Tanprasertsuk; Tammy M Scott; Aron K Barbey; Kathryn Barger; Xiang-Dong Wang; Mary Ann Johnson; Leonard W Poon; Rohini Vishwanathan; Nirupa R Matthan; Alice H Lichtenstein; Guylaine Ferland; Elizabeth J Johnson Journal: Front Nutr Date: 2021-06-29
Authors: Lucia Y Du; Lily Y-L Chang; Alvaro O Ardiles; Cheril Tapia-Rojas; Joaquin Araya; Nibaldo C Inestrosa; Adrian G Palacios; Monica L Acosta Journal: PLoS One Date: 2015-08-12 Impact factor: 3.240